About The Study: This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were uninsured and one-third denied having a routine place for health care—a barrier to identifying, treating, and preventing cardio-kidney-metabolic diseases.
Corresponding Author: To contact the corresponding author, Ashwin K. Chetty, BS, email ashwin.chetty@yale.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamapediatrics.2025.2308)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.2308?guestAccessKey=f2bc51d5-0648-430b-a9be-0407aedaa88c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=080425
JAMA Pediatrics